MiR-502-3P suppresses cell proliferation, migration, and invasion in hepatocellular carcinoma by targeting SET

Background/aim Increasing evidences show that microRNAs are engaged in hepatocellular carcinoma (HCC). The aim of this study was to investigate the role of miR-502-3P in HCC and to identify its underlying mechanism. Methods The expression levels of miR-502-3P were assessed in multiple HCC cell lines and in liver tissues of patients with HCC. We further examined the effects of miR-502-3P on malignant behavior of HCC. The molecular target of miR-502-3P was identified using a computer algorithm and confirmed experimentally. Results Downregulation of miR-502-3P was found in both HCC cell lines and human samples. Overexpression of miR-502-3P dramatically inhibits HCC proliferation, metastasis, invasion, and cell adhesion. We further verify the SET as a novel and direct target of miR-502-3P in HCCs. Conclusion Taken together, overexpression of miR-502-3P or downregulation of SET may prove beneficial as a therapeutic strategy for HCC treatment.

[1]  D. Kleiner,et al.  Identification of microRNAs specifically expressed in hepatitis C virus‐associated hepatocellular carcinoma , 2013, International journal of cancer.

[2]  Huadong Zhou,et al.  MicroRNA-212 inhibits hepatocellular carcinoma cell proliferation and induces apoptosis by targeting FOXA1 , 2015, OncoTargets and therapy.

[3]  Chang-Zheng Chen,et al.  MicroRNAs as oncogenes and tumor suppressors. , 2005, The New England journal of medicine.

[4]  X. Wang,et al.  Stem cell-like micro-RNA signature driven by Myc in aggressive liver cancer , 2010, Proceedings of the National Academy of Sciences.

[5]  Gisèle N'Kontchou,et al.  Iconography : Diagnostic et traitement du carcinome hépatocellulaire chez les malades atteints de cirrhose , 2008 .

[6]  Miin‐Fu Chen.  Icteric type hepatocellular carcinoma: clinical features, diagnosis and treatment. , 2002, Chang Gung medical journal.

[7]  P. Hordijk,et al.  Rac1‐induced cell migration requires membrane recruitment of the nuclear oncogene SET , 2007, The EMBO journal.

[8]  O. Bachs,et al.  The SET Protein Regulates G2/M Transition by Modulating Cyclin B-Cyclin-dependent Kinase 1 Activity* , 2003, The Journal of Biological Chemistry.

[9]  W. Lau,et al.  Hepatocellular carcinoma: current management and recent advances. , 2008, Hepatobiliary & pancreatic diseases international : HBPD INT.

[10]  Thomas D. Schmittgen,et al.  The role of microRNAs in human liver cancers. , 2011, Seminars in oncology.

[11]  Yoshiki Murakami,et al.  Comparison of Hepatocellular Carcinoma miRNA Expression Profiling as Evaluated by Next Generation Sequencing and Microarray , 2014, PloS one.

[12]  Derek Y. Chiang,et al.  MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. , 2011, Gastroenterology.

[13]  Jung-Hwan Yoon,et al.  High expression of microRNA-15b predicts a low risk of tumor recurrence following curative resection of hepatocellular carcinoma. , 2009, Oncology reports.

[14]  A. Prochiantz,et al.  SET protein (TAF1β, I2PP2A) is involved in neuronal apoptosis induced by an amyloid precursor protein cytoplasmic subdomain , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  Y. Peterson,et al.  Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis , 2012, EMBO molecular medicine.

[16]  A. Befeler,et al.  Hepatocellular carcinoma: diagnosis and treatment. , 2002, Gastroenterology.

[17]  George P Cobb,et al.  microRNAs as oncogenes and tumor suppressors. , 2007, Developmental biology.

[18]  Colin J. Daniel,et al.  Targeting Inhibitors of the Tumor Suppressor PP2A for the Treatment of Pancreatic Cancer , 2014, Molecular Cancer Research.

[19]  P. Hordijk,et al.  Cytoplasmic targeting of the proto‐oncogene SET promotes cell spreading and migration , 2013, FEBS letters.

[20]  P. M. Voorhoeve,et al.  MicroRNAs: Oncogenes, tumor suppressors or master regulators of cancer heterogeneity? , 2010, Biochimica et biophysica acta.

[21]  G. Shen,et al.  MicroRNA-26b inhibits epithelial-mesenchymal transition in hepatocellular carcinoma by targeting USP9X , 2014, BMC Cancer.

[22]  Jingcheng Yang,et al.  A Meta-Analysis of MicroRNA Expression in Liver Cancer , 2014, PloS one.

[23]  Yan Ding,et al.  MiR-141 Suppresses the Migration and Invasion of HCC Cells by Targeting Tiam1 , 2014, PloS one.

[24]  Wei Li,et al.  Application of microRNA and mRNA expression profiling on prognostic biomarker discovery for hepatocellular carcinoma , 2014, BMC Genomics.

[25]  Min Li,et al.  Chinese Anti鄄 Cancer a Ssociation , 2022 .

[26]  E. Tajara,et al.  Stable SET knockdown in head and neck squamous cell carcinoma promotes cell invasion and the mesenchymal-like phenotype in vitro, as well as necrosis, cisplatin sensitivity and lymph node metastasis in xenograft tumor models , 2014, Molecular Cancer.

[27]  X. Ren,et al.  Stable SET knockdown in breast cell carcinoma inhibits cell migration and invasion. , 2014, Biochemical and biophysical research communications.